Global economic burden of schizophrenia: a systematic review
- PMID: 26937191
- PMCID: PMC4762470
- DOI: 10.2147/NDT.S96649
Global economic burden of schizophrenia: a systematic review
Abstract
Background: Schizophrenia is one of the top 25 leading causes of disability worldwide in 2013. Despite its low prevalence, its health, social, and economic burden has been tremendous, not only for patients but also for families, caregivers, and the wider society. The magnitude of disease burden investigated in an economic burden study is an important source to policymakers in decision making. This study aims to systematically identify studies focusing on the economic burden of schizophrenia, describe the methods and data sources used, and summarize the findings of economic burden of schizophrenia.
Methods: A systematic review was performed for economic burden studies in schizophrenia using four electronic databases (Medline, EMBASE, PsycINFO, and EconLit) from inception to August 31, 2014.
Results: A total of 56 articles were included in this review. More than 80% of the studies were conducted in high-income countries. Most studies had undertaken a retrospective- and prevalence-based study design. The bottom-up approach was commonly employed to determine cost, while human capital method was used for indirect cost estimation. Database and literature were the most commonly used data sources in cost estimation in high-income countries, while chart review and interview were the main data sources in low and middle-income countries. Annual costs for the schizophrenia population in the country ranged from US$94 million to US$102 billion. Indirect costs contributed to 50%-85% of the total costs associated with schizophrenia. The economic burden of schizophrenia was estimated to range from 0.02% to 1.65% of the gross domestic product.
Conclusion: The enormous economic burden in schizophrenia is suggestive of the inadequate provision of health care services to these patients. An informed decision is achievable with the increasing recognition among public and policymakers that schizophrenia is burdensome. This results in better resource allocation and the development of policy-oriented research for this highly disabling yet under-recognized mental health disease.
Keywords: cost of illness; economic burden; schizophrenia; systematic review.
Figures
Comment in
-
Global economic burden of schizophrenia: letter in response.Neuropsychiatr Dis Treat. 2016 Dec 5;12:3069-3072. doi: 10.2147/NDT.S124867. eCollection 2016. Neuropsychiatr Dis Treat. 2016. PMID: 27980408 Free PMC article. No abstract available.
Similar articles
-
[The cost of schizophrenia: a literature review].Encephale. 2013 May;39 Suppl 1:S49-56. doi: 10.1016/j.encep.2012.11.004. Epub 2013 Jan 23. Encephale. 2013. PMID: 23351935 Review. French.
-
The economic burden of schizophrenia in Malaysia.Neuropsychiatr Dis Treat. 2017 Jul 28;13:1979-1987. doi: 10.2147/NDT.S137140. eCollection 2017. Neuropsychiatr Dis Treat. 2017. PMID: 28814869 Free PMC article.
-
Global Economic Burden of Attention-Deficit/Hyperactivity Disorder: A Systematic Review.Pharmacoeconomics. 2021 Apr;39(4):399-420. doi: 10.1007/s40273-020-00998-0. Epub 2021 Feb 8. Pharmacoeconomics. 2021. PMID: 33554324
-
Cost of depression in Europe.J Ment Health Policy Econ. 2006 Jun;9(2):87-98. J Ment Health Policy Econ. 2006. PMID: 17007486
-
Depression: cost-of-illness studies in the international literature, a review.J Ment Health Policy Econ. 2000 Mar 1;3(1):3-10. doi: 10.1002/1099-176x(200003)3:1<3::aid-mhp68>3.0.co;2-h. J Ment Health Policy Econ. 2000. PMID: 11967432
Cited by
-
Real-World Effectiveness, Economic, and Humanistic Outcomes of Selected Oral Antipsychotics in Patients with Schizophrenia: A Systematic Review Evaluating Global Evidence.Clinicoecon Outcomes Res. 2024 Sep 6;16:621-645. doi: 10.2147/CEOR.S469024. eCollection 2024. Clinicoecon Outcomes Res. 2024. PMID: 39257455 Free PMC article. Review.
-
"Why I stay in community psychiatric rehabilitation": a semi-structured survey in persons with schizophrenia.BMC Psychol. 2022 Sep 6;10(1):213. doi: 10.1186/s40359-022-00919-0. BMC Psychol. 2022. PMID: 36068639 Free PMC article.
-
Insights into the Promising Prospect of G Protein and GPCR-Mediated Signaling in Neuropathophysiology and Its Therapeutic Regulation.Oxid Med Cell Longev. 2022 Sep 21;2022:8425640. doi: 10.1155/2022/8425640. eCollection 2022. Oxid Med Cell Longev. 2022. PMID: 36187336 Free PMC article. Review.
-
Diminished Auditory Cortex Dynamic Range and its Clinical Correlates in First Episode Psychosis.Schizophr Bull. 2023 May 3;49(3):679-687. doi: 10.1093/schbul/sbac208. Schizophr Bull. 2023. PMID: 36749310 Free PMC article.
-
Temporal Trends in the Incidence and Disability Adjusted Life Years of Schizophrenia in China Over 30 Years.Front Psychiatry. 2022 Mar 9;13:831188. doi: 10.3389/fpsyt.2022.831188. eCollection 2022. Front Psychiatry. 2022. PMID: 35356721 Free PMC article.
References
-
- Vos T, Barber RM, Bell B, et al. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990–2013: a systematic analysis for the global burden of disease study 2013. Lancet. 386(9995):743–800. - PMC - PubMed
-
- World Health Organization (WHO) Mental Health: New Understanding, New Hope. Geneva: WHO; 2001.
-
- Jablensky A. The 100-year epidemiology of schizophrenia. Schizophr Res. 1997;28(2–3):111–125. - PubMed
-
- Barbato A. Schizophrenia and Public Health. Geneva: World Health Organization; 1998.
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical